Total Payments
$3.0M
2023 Payments
$167,700
Companies
3
Transactions
384
Payment Breakdown by Category
Consulting$2.8M (94.4%)
Research$119,740 (4.0%)
Travel$47,360 (1.6%)
Food & Beverage$2,340 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $2.8M | 57 | 94.4% |
| Unspecified | $119,740 | 173 | 4.0% |
| Travel and Lodging | $47,360 | 88 | 1.6% |
| Food and Beverage | $2,340 | 66 | 0.1% |
Payments by Type
General
$2.9M
211 transactions
Research
$119,740
173 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, Inc. | $3.0M | 379 | $0 (2023) |
| Biohaven Pharmaceuticals, Inc. | $6,375 | 2 | $0 (2020) |
| Biohaven Pharmaceutical Holding Company Ltd. | $2,415 | 3 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $167,700 | 7 | Otsuka Pharmaceutical Development & Commercialization, Inc. ($167,700) |
| 2022 | $946,103 | 118 | Otsuka Pharmaceutical Development & Commercialization, Inc. ($943,688) |
| 2021 | $833,300 | 13 | Otsuka Pharmaceutical Development & Commercialization, Inc. ($833,300) |
| 2020 | $939,596 | 69 | Otsuka Pharmaceutical Development & Commercialization, Inc. ($933,221) |
| 2019 | $48,924 | 5 | Otsuka Pharmaceutical Development & Commercialization, Inc. ($48,924) |
| 2018 | $27,353 | 156 | Otsuka Pharmaceutical Development & Commercialization, Inc. ($27,353) |
| 2017 | $50,373 | 16 | Otsuka Pharmaceutical Development & Commercialization, Inc. ($50,373) |
All Payment Transactions
384 individual payment records from CMS Open Payments — Page 1 of 16
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/06/2023 | Otsuka Pharmaceutical Development & Commercialization, Inc. | REXULTI (Drug) | Consulting Fee | Cash or cash equivalent | $11,600.00 | General |
| Category: PSYCHIATRY | ||||||
| 05/25/2023 | Otsuka Pharmaceutical Development & Commercialization, Inc. | REXULTI (Drug) | Consulting Fee | Cash or cash equivalent | $24,800.00 | General |
| Category: PSYCHIATRY | ||||||
| 05/22/2023 | Otsuka Pharmaceutical Development & Commercialization, Inc. | REXULTI (Drug) | Consulting Fee | Cash or cash equivalent | $9,400.00 | General |
| Category: PSYCHIATRY | ||||||
| 04/25/2023 | Otsuka Pharmaceutical Development & Commercialization, Inc. | REXULTI (Drug) | Consulting Fee | Cash or cash equivalent | $16,900.00 | General |
| Category: PSYCHIATRY | ||||||
| 04/18/2023 | Otsuka Pharmaceutical Development & Commercialization, Inc. | REXULTI (Drug) | Consulting Fee | Cash or cash equivalent | $48,300.00 | General |
| Category: PSYCHIATRY | ||||||
| 04/11/2023 | Otsuka Pharmaceutical Development & Commercialization, Inc. | REXULTI (Drug) | Consulting Fee | Cash or cash equivalent | $36,500.00 | General |
| Category: PSYCHIATRY | ||||||
| 03/17/2023 | Otsuka Pharmaceutical Development & Commercialization, Inc. | REXULTI (Drug) | Consulting Fee | Cash or cash equivalent | $20,200.00 | General |
| Category: PSYCHIATRY | ||||||
| 12/15/2022 | Otsuka Pharmaceutical Development & Commercialization, Inc. | REXULTI (Drug) | Consulting Fee | Cash or cash equivalent | $62,000.00 | General |
| Category: PSYCHIATRY | ||||||
| 12/12/2022 | Otsuka Pharmaceutical Development & Commercialization, Inc. | REXULTI (Drug) | Consulting Fee | Cash or cash equivalent | $76,700.00 | General |
| Category: PSYCHIATRY | ||||||
| 12/12/2022 | Otsuka Pharmaceutical Development & Commercialization, Inc. | REXULTI (Drug) | Consulting Fee | Cash or cash equivalent | $57,100.00 | General |
| Category: PSYCHIATRY | ||||||
| 11/17/2022 | Otsuka Pharmaceutical Development & Commercialization, Inc. | REXULTI (Drug) | Travel and Lodging | Cash or cash equivalent | $1,695.20 | General |
| Category: PSYCHIATRY | ||||||
| 11/17/2022 | Otsuka Pharmaceutical Development & Commercialization, Inc. | REXULTI (Drug) | Travel and Lodging | Cash or cash equivalent | $996.70 | General |
| Category: PSYCHIATRY | ||||||
| 11/17/2022 | Otsuka Pharmaceutical Development & Commercialization, Inc. | REXULTI (Drug) | Travel and Lodging | Cash or cash equivalent | $875.43 | General |
| Category: PSYCHIATRY | ||||||
| 11/17/2022 | Otsuka Pharmaceutical Development & Commercialization, Inc. | REXULTI (Drug) | Travel and Lodging | Cash or cash equivalent | $428.07 | General |
| Category: PSYCHIATRY | ||||||
| 11/17/2022 | Otsuka Pharmaceutical Development & Commercialization, Inc. | REXULTI (Drug) | Travel and Lodging | Cash or cash equivalent | $303.51 | General |
| Category: PSYCHIATRY | ||||||
| 11/17/2022 | Otsuka Pharmaceutical Development & Commercialization, Inc. | REXULTI (Drug) | Travel and Lodging | Cash or cash equivalent | $272.58 | General |
| Category: PSYCHIATRY | ||||||
| 11/17/2022 | Otsuka Pharmaceutical Development & Commercialization, Inc. | REXULTI (Drug) | Travel and Lodging | Cash or cash equivalent | $194.87 | General |
| Category: PSYCHIATRY | ||||||
| 11/17/2022 | Otsuka Pharmaceutical Development & Commercialization, Inc. | REXULTI (Drug) | Travel and Lodging | Cash or cash equivalent | $158.08 | General |
| Category: PSYCHIATRY | ||||||
| 11/17/2022 | Otsuka Pharmaceutical Development & Commercialization, Inc. | REXULTI (Drug) | Travel and Lodging | Cash or cash equivalent | $98.00 | General |
| Category: PSYCHIATRY | ||||||
| 11/17/2022 | Otsuka Pharmaceutical Development & Commercialization, Inc. | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $75.56 | General |
| Category: PSYCHIATRY | ||||||
| 11/17/2022 | Otsuka Pharmaceutical Development & Commercialization, Inc. | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $66.46 | General |
| Category: PSYCHIATRY | ||||||
| 11/17/2022 | Otsuka Pharmaceutical Development & Commercialization, Inc. | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $60.49 | General |
| Category: PSYCHIATRY | ||||||
| 11/17/2022 | Otsuka Pharmaceutical Development & Commercialization, Inc. | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $50.22 | General |
| Category: PSYCHIATRY | ||||||
| 11/17/2022 | Otsuka Pharmaceutical Development & Commercialization, Inc. | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $31.50 | General |
| Category: PSYCHIATRY | ||||||
| 11/17/2022 | Otsuka Pharmaceutical Development & Commercialization, Inc. | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $30.37 | General |
| Category: PSYCHIATRY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 3, 12-WEEK, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 2-ARM, FIXED-DOSE TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF BREXPIPRAZOLE OPC34712 IN THE TREATMENT OF SUBJECTS WITH AGITATION ASSOCIATED WITH DEMENTIA OF THE ALZHEIMERS TYPE | Otsuka Pharmaceutical Development & Commercialization, Inc. | $28,218 | 32 |
| A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-AND ACTIVE-CONTROLLEDTRIAL TO EVALUATE THE EFFICACY OF BREXPIPRAZOLE MONOTHERAPY FOR THE TREATMENT IN ADOLESCENTS 13-17 YEARS OLD WITH SCHIZOPHRENIA | Otsuka Pharmaceutical Development & Commercialization, Inc. | $24,837 | 54 |
| SAFETY AND TOLERABILITY STUDY OF FLEXIBLE DOSING OF BREXPIPRAZOLE IN THE TREATMENT OF SUBJECTS WITH AGITATION ASSOCIATED WITH DEMENTIA OF THE ALZHEIMER'S TYPE | Otsuka Pharmaceutical Development & Commercialization, Inc. | $19,821 | 2 |
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PLACEBO-CONTROLLED, PARALLEL-GROUP TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CENTANAFADINE SUSTAINED-RELEASE TABLETS IN ADULTS WITH ATTENTION-DEFICITHYPERACTIVITY DISORDER TRIAL 405-201-00013 | Otsuka Pharmaceutical Development & Commercialization, Inc. | $17,129 | 49 |
| A 52-week, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Intramuscular Depot Formulation of Aripiprazole (OPC-14597) as Maintenance Treatment in Patients with Bipolar I Disorder | Otsuka Pharmaceutical Development & Commercialization, Inc. | $8,677 | 3 |
| PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- AND ACTIVE-CONTROLLED TRIAL OF BREXPIPRAZOLE 1 - 3 MGDAY AS MONOTHERAPY OR AS COMBINATION THERAPY IN THE TREATMENT OF ADULTS WITH POST-TRAUMATIC STRESS DISORDER | Otsuka Pharmaceutical Development & Commercialization, Inc. | $4,315 | 13 |
| A Phase 1, Single-dose, Sequential Cohort, Nonrandomized Crossover Trial to Assess the Pharmacokinetics, Safety, and Tolerability of Oral Brexpiprazole in Children (6 to < 13 Years old) With Central Nervous System Disorders | Otsuka Pharmaceutical Development & Commercialization, Inc. | $4,141 | 1 |
| A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of OPC-34172 in the Treatment of Adolescent Patients with Schizophrenia | Otsuka Pharmaceutical Development & Commercialization, Inc. | $3,209 | 1 |
| STUDY EVALUATING THE SAFETY AND EFFICACY OF FIXED-DOSE ONCE-DAILY ORAL ARIPIPRAZOLE IN CHILDREN AND ADOLESCENTS WITH TOURETTE'S DISORDER31-12-293 | Otsuka Pharmaceutical Development & Commercialization, Inc. | $2,622 | 1 |
| AN OPEN-LABEL, RANDOMIZED, 2-WAY CROSSOVER, PILOT TRIAL TO ASSESS THE BIOEQUIVALENCE OF ORAL DOSES OF DM-R NO IEMVERSUS RISPERDAL TABLETS IN HEALTHY SUBJESCT. | Otsuka Pharmaceutical Development & Commercialization, Inc. | $2,075 | 1 |
| A STUDY OF THREE FIXED-DOSES OF BREXPIPRAZOLE IN THE TREATMENT OF SUBJECTS WITH AGITATION ASSOCIATED WITH DEMENTIA OF THE ALZHEIMER'S TYPE | Otsuka Pharmaceutical Development & Commercialization, Inc. | $1,851 | 2 |
| A PHASE 1, SINGLE-DOSE, SEQUENTIAL COHORT, NONRANDOMIZED CROSSOVER TRIAL TO ASSESS THE PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF ORAL BREXPIPRAZOLE IN CHILDREN 6 TO 13 YEARS OLD WITH CENTRAL NERVOUS SYSTEM DISORDERS | Otsuka Pharmaceutical Development & Commercialization, Inc. | $1,747 | 12 |
| A Phase 3, Randomized, Double-blind, Multicenter, Placebo-controlled, Parallel-group Trial Evaluating the Efficacy, Safety, and Tolerability of Centanafadine Sustained-Release in Adults with Attention-Deficit/Hyperactivity Disorder | Otsuka Pharmaceutical Development & Commercialization, Inc. | $1,016 | 1 |
| A PHASE 3, 12-WEEK, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 2-ARM, FIXED-DOSE TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF BREXPIPRAZOLE (OPC34712) IN THE TREATMENT OF SUBJECTS WITH AGITATION ASSOCIATED WITH DEMENTIA OF THE ALZHEIMERS TYPE | Otsuka Pharmaceutical Development & Commercialization, Inc. | $81.63 | 1 |
About Dr. Kevin Cox, MD
Dr. Kevin Cox, MD is a Child & Adolescent Psychiatry healthcare provider based in Ojai, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/25/2007. The National Provider Identifier (NPI) number assigned to this provider is 1538214614.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Kevin Cox, MD has received a total of $3.0M in payments from pharmaceutical and medical device companies, with $167,700 received in 2023. These payments were reported across 384 transactions from 3 companies. The most common payment nature is "Consulting Fee" ($2.8M).
Ad
Practice Information
- Specialty Child & Adolescent Psychiatry
- Location Ojai, CA
- Active Since 01/25/2007
- Last Updated 07/08/2007
- Taxonomy Code 2084P0804X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1538214614
Products in Payments
- REXULTI (Drug) $3.0M
- ABILIFY MAINTENA (Drug) $8,677
- ABILIFY TABLET (Drug) $2,622
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.